Related Experiment Video
Updated: Dec 7, 2025
05:14
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
1.4K
Ranibizumab for myopic choroidal neovascularization
Danny S C Ng1, Nicholas S K Fung2, Fanny L T Yip3
1The Chinese University of Hong Kong , Kowloon, Hong Kong.
Expert Opinion on Biological Therapy
|October 2, 2020
Summary
Ranibizumab is an approved anti-vascular endothelial growth factor (anti-VEGF) therapy for treating myopic choroidal neovascularization (CNV). While effective and cost-efficient, long-term gains are limited by chorioretinal atrophy, necessitating further research.
Area of Science:
- Ophthalmology
- Medical Retina
- Vascular Biology
Background:
- Pathologic myopia can lead to myopic choroidal neovascularization (CNV), a major cause of vision loss.
- Anti-vascular endothelial growth factor (anti-VEGF) therapy is the current standard of care for myopic CNV.
Purpose of the Study:
- To review the evidence supporting ranibizumab for myopic CNV.
- To discuss its efficacy, safety, and future directions.
Main Methods:
- Review of preclinical studies and clinical trial data.
- Analysis of efficacy, safety, and cost-effectiveness.
Main Results:
- Ranibizumab shows good efficacy and safety in clinical trials for myopic CNV.
- It is the only FDA-approved anti-VEGF drug for this condition and is cost-effective.
Conclusions:
- Ranibizumab is an effective treatment for myopic CNV, but long-term visual gain is limited by chorioretinal atrophy.
- Further research is needed to address chorioretinal atrophy and explore potential biosimilars.
More Related Videos
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
861
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
861
01:28Angle Closure Glaucoma: Treatment
987
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
987
01:25Glaucoma: Overview
1.1K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.1K